Viela Bio

News

AstraZeneca spins out biotech to focus on autoimmune candida...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.

News

EU clears first drug therapy for rare disease cALD

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks